MarketCap
Facebook
X
Telegram
NGM Biopharmaceuticals EBITDA | NGM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA NGM Biopharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149 M | -162 M | -115 M | -97.3 M | -41.7 M | 2.91 M | -11 M | -4.83 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.91 M | -162 M | -72.2 M |
Quarterly EBITDA NGM Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.5 M | -40 M | -49.6 M | - | -47.7 M | -45.7 M | -31.2 M | - | -27.5 M | -35 M | -26.3 M | - | -28.4 M | -23.8 M | -18.9 M | -17.3 M | -11.1 M | -7.81 M | -7.38 M | 13.1 M | -6.57 M | -2.49 M | -2.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | -49.6 M | -22.4 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Magenta Therapeutics
MGTA
|
-178 M | - | -7.74 % | $ 41.6 M |  USA |
 |
NovaBay Pharmaceuticals
NBY
|
-8.44 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-13.7 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
-48.9 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-17.8 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
-156 M | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
-170 M | $ 8.74 | 0.52 % | $ 606 M | USA |
 |
BiomX
PHGE
|
-38.5 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-38.6 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
-14.9 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-24.4 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-13.2 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
-11.1 M | - | -6.08 % | $ 184 M |  China |
 |
Cassava Sciences
SAVA
|
-94.5 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
-141 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
-117 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
-12.6 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
-22.2 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
-15.8 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
-23.9 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
-4.01 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
-28 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
-12 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
6.3 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
14.3 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
-91.6 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-58.8 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
-26.1 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
820 K | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-79.2 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-66.6 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.61 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-30.6 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.8 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-137 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-29.2 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-270 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-135 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-214 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
15.8 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
21.1 M | $ 302.6 | -0.19 % | $ 23.6 B | USA |